Cargando…
Pembrolizumab输注过程中出现低血压：病例报告并文献综述
Immunological checkpoint inhibitors have been approved for a short period of time in China, and real-world clinical data are still in the collection stage. Reports of domestic programmed death-1 (PD-1) treatment-related adverse reactions are rare. The author reported a case of hypotension in the pro...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885412/ https://www.ncbi.nlm.nih.gov/pubmed/31771745 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.11.09 |
| _version_ | 1783474731384569856 |
|---|---|
| collection | PubMed |
| description | Immunological checkpoint inhibitors have been approved for a short period of time in China, and real-world clinical data are still in the collection stage. Reports of domestic programmed death-1 (PD-1) treatment-related adverse reactions are rare. The author reported a case of hypotension in the process of Pembrolizumab infusion and successful infusion after blood pressure recovery, hoping to provide reference for the application of immunological checkpoint inhibitors, to provide patients with the greatest clinical benefit. |
| format | Online Article Text |
| id | pubmed-6885412 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | 中国肺癌杂志编辑部 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-68854122019-12-12 Pembrolizumab输注过程中出现低血压：病例报告并文献综述 Zhongguo Fei Ai Za Zhi 病例报道 Immunological checkpoint inhibitors have been approved for a short period of time in China, and real-world clinical data are still in the collection stage. Reports of domestic programmed death-1 (PD-1) treatment-related adverse reactions are rare. The author reported a case of hypotension in the process of Pembrolizumab infusion and successful infusion after blood pressure recovery, hoping to provide reference for the application of immunological checkpoint inhibitors, to provide patients with the greatest clinical benefit. 中国肺癌杂志编辑部 2019-11-20 /pmc/articles/PMC6885412/ /pubmed/31771745 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.11.09 Text en 版权所有©《中国肺癌杂志》编辑部2019 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
| spellingShingle | 病例报道 Pembrolizumab输注过程中出现低血压：病例报告并文献综述 |
| title | Pembrolizumab输注过程中出现低血压：病例报告并文献综述 |
| title_full | Pembrolizumab输注过程中出现低血压：病例报告并文献综述 |
| title_fullStr | Pembrolizumab输注过程中出现低血压：病例报告并文献综述 |
| title_full_unstemmed | Pembrolizumab输注过程中出现低血压：病例报告并文献综述 |
| title_short | Pembrolizumab输注过程中出现低血压：病例报告并文献综述 |
| title_sort | pembrolizumab输注过程中出现低血压：病例报告并文献综述 |
| topic | 病例报道 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885412/ https://www.ncbi.nlm.nih.gov/pubmed/31771745 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.11.09 |
| work_keys_str_mv | AT pembrolizumabshūzhùguòchéngzhōngchūxiàndīxuèyābìnglìbàogàobìngwénxiànzōngshù AT pembrolizumabshūzhùguòchéngzhōngchūxiàndīxuèyābìnglìbàogàobìngwénxiànzōngshù AT pembrolizumabshūzhùguòchéngzhōngchūxiàndīxuèyābìnglìbàogàobìngwénxiànzōngshù |